"This is a totally new mechanism for how these host proteins are activated," Hobbs said. "I never would have guessed that this was the way it was going to work."

In effect, the bacterium turns the virus's own weapon into evidence of the attack. The phage needs its protease to replicate, but the moment that enzyme touches the bacterial sensor, the host condemns itself to death and starves the virus of further victims.

Why does this matter for medicine?

Scientists are increasingly interested in phage therapy as an alternative to antibiotics. Phages kill bacteria without harming human cells, and they can attack bacteria that have become resistant to standard drugs.

But phage therapy faces a major obstacle: bacteria are not defenseless. They carry evolved immune systems that can block therapeutic phages. Understanding exactly how defenses like CBASS detect viruses could help researchers design phages that evade or overcome those defenses, making treatments more reliable.

Any clinical applications remain distant, however. The current study is basic research conducted in bacteria, and it does not test therapy in animals or people. Its immediate value is explanatory: it defines a detection mechanism that was previously unknown.

What does CBASS reveal about human immunity?

The discovery also reaches beyond bacteria. CBASS is related to an immune pathway found in humans, which suggests that parts of this antiviral defense have survived across an enormous span of evolutionary history — dating back at least to the common ancestor shared by bacteria and humans.

"The fact that these systems are conserved between bacteria and humans suggests that they've been maintained in these different organisms for that entire evolutionary trajectory," Hobbs said. "The cells are telling us that this is a really important pathway because they've maintained it for billions of years."

Bacteria also offer a practical advantage for immunology research. Their rapid life cycles let scientists study immune processes quickly and then test what they learn in biological models more closely related to humans.

"It's incredibly fascinating, and it's a cool window into what's important in maintaining the ability to fight viruses," Hobbs said.

What are the study's limitations?

The research describes a mechanism in a specific bacterial immune system, and several questions remain open. The study does not claim that all CBASS variants detect phages the same way, and translating the finding into improved phage therapies will require additional work — engineering phages that bypass CBASS and testing them against antibiotic-resistant bacteria in real infections.

The study appeared in Science, volume 394, issue 6819, page 102 (DOI: 10.1126/science.aeg3949). Support came from the Pew Biomedical Scholars program, the Burroughs Wellcome Fund, the G. Harold and Leila Y. Mathers Foundation, the Cancer Research Institute, the Parker Institute for Cancer Immunotherapy, the Massachusetts Consortium on Pathogen Readiness, and the National Institute of General Medical Sciences of the National Institutes of Health.